Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. Next up, the complement inhibitor—which AZ ...

AstraZeneca’s Ultomiris shows promise in rare post-transplant complication There are currently no approved treatment options for HSCT-TMA AstraZeneca (AZ) has announced promising results from a ...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients. A biologic medicine ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Initiative’s growth came almost entirely from 11 existing pharma clients, including AstraZeneca, Bristol Myers Squibb, Merck and Gilead. It added work from Alexion Pharmaceuticals for Ultomiris.

Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others.

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...